Biomarkers · Cardiometabolic
Homoarginine
Higher values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
Homoarginine and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in Homoarginine, study by study
3 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| supplement | L-homoarginine 125 mg once daily by mouth for 4 weeks in healthy young volunteers | Peak plasma L-homoarginine rises by 17.3 umol/L (95% CI 14.9-19.6) above a 2.87 umol/L baseline one hour after dosing following 4 weeks (+8.74 after a single dose); about sevenfold increase | RCT | Atzler D, Schonhoff M, Cordts K, et al. Oral supplementation with… |
Things that worsen it
| Type | Condition or exposure | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Empagliflozin for 6 weeks in patients with type 2 diabetes (placebo-controlled crossover) | Plasma L-homoarginine 17.5% lower after 6 weeks of empagliflozin (P<0.001); SDMA +6.7% | RCT | Gessner A, Gemeinhardt A, Bosch A, et al. Cardiovasc Diabetol. 2022. |
Sources
- Risk curve: Schwedhelm 2020 (PMID 32604958): all-cause HR 0.83 (0.74-0.93) per SD increment in plasma homoarginine. Scaled to published population values.
- Schwedhelm et al. Association of Lower Plasma Homoarginine Concentrations with Greater Risk of All-Cause Mortality in the Community: The Framingham Offspring Study. Journal of clinical medicine. 2020;9:.
Map Homoarginine against another biomarker.
Related markers: Apolipoprotein B to A1 Ratio (ApoB/ApoA1) · Asymmetric Dimethylarginine (ADMA) · Lipid Accumulation Product (LAP) · Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) · Metabolic Syndrome (Harmonized Definition) · Non-HDL Cholesterol · Trimethylamine N-oxide (TMAO)